Document is current

Article History

Received: 13 July 2019

Accepted: 23 September 2019

First Online: 22 October 2019

Conflict of interest

: M. Pez, A. Keller, B. Tuschy, and S. Berlit declare that they have no competing interests. G. Welzel reports non-financial support from Carl Zeiss Meditec AG and personal fees from Roche Pharma AG outside the submitted work. Y. Abo-Madyan reports honoraria from Carl-Zeiss Meditec outside the submitted work, honoraria from Merck-Serono outside the submitted work, personal fees from Elekta. M. Ehmann reports travel grants from Carl Zeiss meditec AG outside the submitted work. M. Sütterlin reports personal fees and travel grants from Carl Zeiss Meditec AG outside the submitted work. F. Wenz reports personal fees from Celgene GmbH, personal fees from Roche Pharma AG, personal fees from Eli Lilly and Company, personal fees from Ipsen Pharma GmbH, research and travel grants from Carl Zeiss Meditec AG and from ELEKTA AB outside the submitted work. F. Wenz also holds a patent in collaboration with Carl Zeiss Meditec AG. F.A. Giordano reports grants and personal fees from NOXXON Pharma AG, grants and personal fees from CARL ZEISS MEDITEC AG, personal fees from Bristol-Myers Squibb, personal fees from Roche Pharma AG, personal fees from MSD Sharp and Dohme GmbH, personal fees from AstraZeneca GmbH, outside the submitted work; F.A. Giordano is the founder of Implacit GmbH, and reports non-financial support (using software for free) from Oncare GmbH; In addition, F.A. Giordano has a patent (US 62/435405) pending. E. Sperk reports grants from the Ministry for Science and Arts during the conduct of the study; personal fees and travel grants from Zeiss Meditec AG, outside the submitted work.